Role of CYP1A2 polymorphisms in breast cancer risk in women

  • Authors:
    • Imene Ayari
    • Ugo Fedeli
    • Saad Saguem
    • Samir Hidar
    • Saida Khlifi
    • Sofia Pavanello
  • View Affiliations

  • Published online on: November 1, 2012     https://doi.org/10.3892/mmr.2012.1164
  • Pages: 280-286
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cytochrome P4501A2 (CYP1A2) is a key enzyme in the etiology of breast cancer (BC). It is involved in breast carcinogen activation [aromatic (AAs) and heterocyclic amines (HAs), polycyclic aromatic hydrocarbons (PAHs)], in the production of beneficial oestrogen [2-hydroxyestrone (2-OHE1)] and in converting arachidonic acid (AAc) to epoxyeicosatrienoic acids (EETs), which have anti-inflammatory properties. Within a hospital-based case-control study, the effect of functional CYP1A2 variants [-3860G/A (rs2069514), -2467T/delT (rs3569413), -163C/A (rs762551)] and their interactions with environmental factors in BC risk was investigated. The study population included 125 BC cases and 43 non-cancer controls. Genotyping was performed in RT-PCR using Taqman assays. The gene-environment interaction was appraised using a case-only study design. We found that the -3860A variant, independently from environmental factors, as well as by interacting with fried foods (p=0.025) and indoor exposure to pollutants (p=0.050), reduced the risk of BC (p=0.025), whereas its interaction with coffee (p=0.045) increased the BC risk. This is the first study indicating that the -3860A variant, by decreasing CYP1A2 activity, modifies BC risk by interacting with environmental factors, thereby supporting the hypothesis that reduced CYP1A2 activity contributes to BC risk in different ways, for example, it may be protective by reducing the activation of pro-carcinogens such as AAs, HAs and PAHs, but would increase risk by reducing the beneficial formation of 2-OHE1 and EETs.
View References

Related Articles

Journal Cover

January 2013
Volume 7 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ayari I, Fedeli U, Saguem S, Hidar S, Khlifi S and Pavanello S: Role of CYP1A2 polymorphisms in breast cancer risk in women. Mol Med Rep 7: 280-286, 2013.
APA
Ayari, I., Fedeli, U., Saguem, S., Hidar, S., Khlifi, S., & Pavanello, S. (2013). Role of CYP1A2 polymorphisms in breast cancer risk in women. Molecular Medicine Reports, 7, 280-286. https://doi.org/10.3892/mmr.2012.1164
MLA
Ayari, I., Fedeli, U., Saguem, S., Hidar, S., Khlifi, S., Pavanello, S."Role of CYP1A2 polymorphisms in breast cancer risk in women". Molecular Medicine Reports 7.1 (2013): 280-286.
Chicago
Ayari, I., Fedeli, U., Saguem, S., Hidar, S., Khlifi, S., Pavanello, S."Role of CYP1A2 polymorphisms in breast cancer risk in women". Molecular Medicine Reports 7, no. 1 (2013): 280-286. https://doi.org/10.3892/mmr.2012.1164